Tixagevimab (AZD8895) is a human monoclonal antibody that targets the SARS-CoV-2 receptor binding domain (RBD). It exhibits neutralizing activity against SARS-CoV-2 by binding to the RBD and the S-glycoprotein ectodomain and blocking S-glycoprotein-mediated binding to the receptor.
Tixagevimab can be combined with Cilgavimab to form AZD7442. AZD7442 (2, 4 or 16 mg/kg, i.v.) results in a dose-dependent decrease in lung infection titres and viral RNA levels and a significant reduction in infection titers at the 16 mg/kg dose compared to animals at the 2 mg/kg dose in hamsters infected with strain G614 or in hamsters infected with the Omicron variant[2].
References:
[1]. Jinhui Dong, et al. Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail. Nat Microbiol. 2021 Oct;6(10):1233-1244.
[2]. Jean-Sélim DRIOUICH, et al. Activity of Tixagevimab/Cilgavimab against the Omicron variant of SARS-CoV-2 in a hamster model.